Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO. Since current antiviral therapies do not provide a curative treatment for the 296 million HBV carriers around the globe, novel strategies to c...

Full description

Bibliographic Details
Main Authors: Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Ulrike Protzer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
HBV cure
adoptive T-cell therapy
T-cell engager antibody
drug development
chronic hepatitis B
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1029214/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1029214/full

Similar Items